The russian experience of vaccination against pneumococcal infection in adults from risk groups
https://doi.org/10.24884/1609-2201-2024-103-4-40-46
Abstract
Pneumococcal infection remains a serious problem in practical health care, being one of the most common causes of death from infectious diseases. Vaccination is the only way to significantly affect the morbidity and mortality from pneumococcal infection and reduce the level of resistance to antibacterial drugs. The article analyzes the experience of vaccination against pneumococcal infection in adults from risk groups.
About the Authors
I. V. Demko
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Regional state budgetary healthcare institution "Regional Clinical Hospital" of Krasnoyarsk
Russian Federation
Russian Federation
Irina V. Demko - Dr. of Sci. (Med.), Professor, Head of Department of Hospital Therapy and Immunology with Postgraduate Education Course, Professor V. F. Voino-Yasenetsky Krasnoyarsk SMU, Head of Pulmonary Allergology Сenter, Regional Clinical Hospital of Krasnoyarsk.
Krasnoyarsk
N. V. Gordeeva
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Regional state budgetary healthcare institution "Regional Clinical Hospital" of Krasnoyarsk
Russian Federation
Russian Federation
Natalia V. Gordeeva -Cand. of Sci. (Med.), Associate Professor of Department of Hospital Therapy and Immunology with Postgraduate Education Course, Professor V. F. Voino-Yasenetsky Krasnoyarsk SMU, Pulmonologist, pulmonology department, Regional Clinical Hospital of Krasnoyarsk.
Krasnoyarsk
E. S. Torgunakova
Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation
Russian Federation
Ekaterina S. Torgunakova - a postgraduate student, assistant of Department of Hospital Therapy and Immunology with Postgraduate Education Course.
1, P. Zeleznyak street, Krasnoyarsk, 660022
References
1. Bayanova T. A., Stukova E. S., Kravchenko N. A. Effect of vaccination on morbidity and mortality from community-acquired pneumonia. Acta biomedicascientifica. 2024;9(1):241–250. (In Russ.). https://doi.org/10.29413/ABS.2024-9.1.24.
2. On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2023: State Report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Welfare Rospotrebnadzor, 2024. 364 p. (In Russ.).
3. Community-acquired pneumonia in adults: Federal clinical guidelines. 2021. (In Russ.).
4. Vila-Corcoles A., Ochoa-Gondar O., Vila-Rovira A. et al. Incidence and Risk of Pneumococcal Pneumonia in Adults with Distinct Underlying Medical Conditions: A Population-Based Study. Lung. 2020;198(3):481–489. https://doi.org/10.1007/s00408-020-00349-y.
5. Avdeev S. N., Belotserkovskiy B. Z., Dehnich A. V. et al. Modern approaches to the diagnostics, treatment and prevention of severe community-acquired pneumonia in adults: a review. Annals of Critical Care. 2021;3:27–46. (In Russ.). https://doi.org/10.21320/1818-474X-2021-3-27-46.
6. Shoar S., Musher D. M. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia. 2020;12:11. https://doi.org/10.1186/s41479-020-00074-3.
7. Rachina S., Zakharenkov I., Dekhnich N. et al. Aetiology of severe community-acquired pneumonia and antimicrobial susceptibility of Streptococcus pneumoniae in adults in Russia. J Antimicrob Chemother. 2021;76(5):1368–1370. https://doi.org/10.1093/jac/dkab014.
8. Avdeev S. N., Alyeva M. H., Baranov A. A. et al. Federal Clinical Guidelines on Vaccination of pneumococcal infection in children and adults. Russian Journal of Preventive Medicine. 2023;26(92):323.(In Russ.).https://doi.org/10.17116/profmed2023260923.
9. Ritchie H. Vaccines have saved 150 million children over the last 50 years. OurWorldinData.org. 2024. URL: https://ourworldindata.org/vaccines-children-saved’ (accessed: 20.12.24).
10. Briko N. I., Korshunov V. A., Vasilyeva I. A., Vorobieva A. D. Vaccination against pneumococcal infection in adults from risk groups. Tuberculosis and Lung Diseases. 2020;98(5):15–23. (In Russ.). http://doi.org/10.21292/2075-1230-2020-98-5-15-23.
11. Chuchalin A. G., Briko N. I., Avdeev S. N. et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19–34. (In Russ.). https://doi.org/10.18093/0869-0189-2019-29-1-19-34.
12. Ignatova G. L., Blinova E. V., Antonov V. N. Analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with type 2 diabetes mellitus. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(1):100–106. (In Russ.). https://doi.org/10.26442/00403660.2022.01.201378.
13. Pollard A. J., Perrett K. P., Beverley P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–220. https://doi.org/10.1038/nri2494.
14. Instructions for use of the drug for medical use Preventar 13 (pneumococcal polysaccharide conjugated adsorbed vaccine, thirteen-valent). URL: http://grls.rosminzdrav.ru/grls.aspx?s=превенар&m=tn (accessed: 03.11.2024).
15. Demko I. V., Korchagin E. E., Gordeeva N. V. et al. Features of severe course and fatal outcomes of community-acquired pneumonia at the example of Krasnoyarsk Region. Bülleten’ fi-ziologii i patologii dyhaniä = Bulletin Physiology and Pathology of Respiration. 2017;27(1):21–28. (In Russ.). https://doi.org/10.18093/0869-0189-2017-27-1-21-28.
16. Benito N., Moreno A., Miro J. M., Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J. 2012;39(3):730–45. https://doi.org/10.1183/09031936.00200210. PMID: 21885385.
17. Zhestkov A. V., Zolotov M. O., Lyamin A. V. et al. Experience with 13-valent conjugated pneumococcal vaccine in HIV-infected patients. Therapeutic Archive. 2020;92(11):38–44. (In Russ.). https://doi.org/10.26442/00403660.2020.11.000861.
18. Hosuru Subramanya S., Thapa S., Dwedi S. K. et al. Streptococcus pneumoniae and Haemophilus species colonization in health care workers: the launch of invasive infections?. BMC Res Notes. 2016;9:66. https://doi.org/10.1186/s13104016-1877-x.
19. Shpagina L. A., Kotova O. S., Shpagin I. S. et al. Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers. Therapeutic Archive. 2018;90(11):55–61. (In Russ.). https://doi.org/10.26442/terarkh201890114-61.
Review
For citations:
Demko I.V., Gordeeva N.V., Torgunakova E.S. The russian experience of vaccination against pneumococcal infection in adults from risk groups. New St. Petersburg Medical Records. 2024;(4):40-46. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-4-40-46
Views:
65
Email this article 